On May 23, 2022, SK-Pharmacy LLP Single Distributor held a meeting with representatives of the Pakistani pharmaceutical company CCL Pharmaceuticals, where plans to expand cooperation in the field of pharmaceuticals were discussed.
CCL Pharmaceuticals was represented at the meeting by Atif Idris Siddiqui, President of the company, and Syed Umair Maruf, Head of Business for South Asia, Africa and the CIS.
These days, on May 19-23, Made in Pakistan 2022 exhibition is being held in Almaty with the assistance of the Embassy of the Republic of Kazakhstan in the Islamic Republic of Pakistan and personally Ambassador Yerzhan Kistafin. Within the framework of this exhibition, where 60 manufacturers of Pakistan from different industries participate, manufacturers of medicines and medical devices are also represented, including the pharmaceutical company CCL Pharmaceuticals, which is interested in localizing production in the territory of the Republic of Kazakhstan.
CCL Pharmaceuticals strives to build partnerships with the healthcare system of the Republic of Kazakhstan, therefore, the issues of technology transfer and consideration of the possibility of building a plant in Kazakhstan were particularly raised at the meeting.
It should be noted that the opening of a new plant would give a new impetus to the development of cooperation and would demonstrate the readiness of manufacturers of the two countries to deeply localize innovative drugs.
It should be considered that in the case of medicines, technology transfer should also take into account issues of quality, safety and effectiveness of medicines, compliance with which is a
Thus, Single Distributor takes the initiative to provide a platform for the entry of large pharmaceutical brands into the country from packaging to a full production cycle in order to support the development of domestic pharmaceutical production.
The Head of State noted the importance of cooperation with global pharmaceutical corporations, attracting investors, ensuring the transfer of technologies and the latest developments.
During the implementation of measures for the development of the pharmaceutical industry in Kazakhstan, Single Distributor holds meetings with major players in the global pharmaceutical industry, during which their long-term plans for presence in the Kazakh pharmaceutical market and issues of investment in the industry are discussed.
The development of the production of expensive innovative products, the promotion of the industry in the direction of technology transfer, localization of original medicines and the production of substances, is of key importance for the industry today. The Government of Kazakhstan has adopted and is already implementing a comprehensive plan for the development of the pharmaceutical industry until 2025, HEALTHY NATION National project for 2021-2025 has been developed, where one of the directions is the development of pharmaceutical science and the creation of new industries with the participation of world players.
It is noteworthy that this year marks exactly 30 years since the establishment of diplomatic relations between the Republic of Kazakhstan and the Islamic Republic of Pakistan. Kazakh-Pakistani relations have always reflected friendly intentions between our countries.
By the end of 2021, the trade turnover between the two countries amounted to $95.1 million, while over the past 10 years, the volume of foreign direct investment from Pakistan to Kazakhstan amounted to $16.7 million. And it should be noted that the most interesting from the point of view of investment are such industries as petrochemicals, light industry, pharmaceuticals, logistics and IT.
In 2022, the Single Distributor procured by tender 5 names of medicines manufactured by the Islamic Republic of Pakistan, such as Colistin (Colistimethate) from the manufacturer MTI Medical Pvt Ltd, and Tenofovir, Montelukast, Salmeterol and Fluticasone 25/125 mcg, Salmeterol and Fluticasone 25/250 mcg from the manufacturer Getz Pharma (Htp.) Limited, Pakistan.
Following the meeting, the parties expressed interest in cooperation. It was noted that it is necessary to consolidate joint efforts for mutually beneficial cooperation.
Reference:
CCL Pharmaceuticals is a leading regional multinational pharmaceutical company with more than 50 years of experience. The company, which is among the top twenty national pharmaceutical companies, is actively engaged in the development, production and marketing of generic pharmaceutical products, and it became the first national pharmaceutical company in Pakistan to receive ISO 9001:2000 certification.
CCL company is equipped with the latest production lines, experienced, capable and purposeful professionals and the management is fully focused on the production of medical products of the highest quality. The production sites in Lahore (Pakistan) and Ho Chi Minh City (Vietnam) are equipped with first-class equipment and produce oral solids (tablets, capsules), oral liquids (syrups), dry powder suspensions, liquid injections and dry powder injections. CCL exports its products to Myanmar, Cambodia, Philippines, Sudan, Tanzania, Zambia, Sri Lanka and Afghanistan, and is gradually expanding its export potential to other countries of the world.
List of Top 10 pharmaceutical Companies in Pakistan in 2021:
1. GlaxoSmithKline (https://pk.gsk.com/en-pk/) GlaxoSmithKline (GSK)
2. Getz Pharma (Private) Limited (https://getzpharma.com/)
3. Abbott Laboratories Pakistan Limited (https://www.pk.abbott/)
4. Sami Pharmaceutical (Private) Limited (https://www.samipharmapk.com/)
5. The Searle Company Limited (https://www.searlepakistan.com/)
6. Hilton Pharma (Private) Limited (https://hiltonpharma.com/)
7. Ferozsons Laboratories limited (https://ferozsons-labs.com/)
8. Pfizer Pakistan Limited (https://www.pfizer.com.pk/)
9. Bayer (https://www.bayer.com/en/pk/pakistan-home)
10. Wyeth Pakistan Limited (https://www.wyethpakistan.com/)
.png)
.jpeg)